SOUTH SAN FRANCISCO, Calif.  – Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at two upcoming investor conferences in November.

• Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:00 p.m. ET
• Piper Sandler 33^rd Annual Virtual Healthcare Conference available on Monday, November 22, 2021 at 10:00 a.m. ET

A live audio webcast of each presentation will be available for access in the News & Media section of Frontier’s website (LINK). An archived replay will be accessible for 30 days following each event.

About Frontier Medicines

Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer. The company’s lead program is focused on KRAS^G12C and is distinct in that it targets direct inhibition of both the activated and inactive forms of KRAS^G12C. This KRAS mutation is found most prevalently in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.